Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue
Total revenue	$ 39,467	$ 26,299	$ 116,414	$ 68,197
Operating expenses
Cost of revenue	14,189	6,053	34,945	16,308
Research and development	36,072	30,314	107,644	80,241
Sales and marketing	24,949	14,474	68,769	42,813
General and administrative	20,154	12,079	51,156	36,138
Amortization of intangible assets	428	428	1,270	1,275
Total operating expenses	95,792	63,348	263,784	176,775
Loss from operations	(56,325)	(37,049)	(147,370)	(108,578)
Interest and other income, net	327	1,018	1,429	5,805
Income tax (expense) benefit		(688)		1,116
Net loss	(55,998)	(36,719)	(145,941)	(101,657)
Add: Net loss attributable to noncontrolling interest	95		95
Net loss attributable to Adaptive Biotechnologies Corporation	$ (55,903)	$ (36,719)	$ (145,846)	$ (101,657)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	$ (0.40)	$ (0.27)	$ (1.04)	$ (0.79)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	140,833,564	134,372,026	140,060,379	129,289,948
Sequencing Revenue
Revenue
Total revenue	$ 22,106	$ 11,276	$ 55,835	$ 28,730
Development Revenue
Revenue
Total revenue	$ 17,361	$ 15,023	$ 60,579	$ 39,467